INTRODUCTION
The mammalian gastrointestinal tract is colonized by trillions of microorganisms (the gut microbiota), a large fraction of which are bacteria. This microbial community has an extensive impact on host metabolism with important implications for health (
1–3). The contribution of the gut microbiota to energy harvest from the diet and to fat storage constitutes a key beneficial trait that underlies host-microbiota symbiosis in mammals (
4). However, this contribution has likely become detrimental to modern humans living in societies with excess food resources, as it increases susceptibility to metabolic disorders, such as obesity, type 2 diabetes, and coronary heart disease. Accordingly, the gut microbiota is increasingly being accepted as an important factor that contributes to pathological conditions associated with obesity (
5), and in humans, metabolic pathologies often are associated with alterations in the gut microbiota (which is referred to as dysbiosis) (
6–9). Unfortunately, there is still little consensus on the bacterial groups that are linked to obesity-related diseases and metabolic phenotypes (
3). In addition, although comparisons between germ-free and conventional mice and rats have clearly established a role of the microbiota in modulating host lipid metabolism (
2,
10–12), it remains unclear whether dysbioses contribute to metabolic pathologies. However, such basic information is essential for our understanding of the diet-microbiota-host metabolism interplay, especially for the development of dietary strategies to prevent metabolic disorders through a modulation of the gut microbiome (
3,
13,
14).
Novel molecular technologies based on massive parallel sequencing have enabled the identification of associations between host lipid metabolism and gut microbial community structure in both humans and animals. Two bacterial families, the
Erysipelotrichaceae and
Coriobacteriaceae, have been repeatedly linked to the host lipid metabolism and associated with the dyslipidemic phenotypes. Spencer and coworkers (
8) showed that levels of
Erysipelotrichaceae were positively associated with changes in liver fat in humans, and higher proportions of this bacterial group have been also identified in morbidly obese individuals (
9).
Erysipelotrichaceae have been also linked to lipidemic imbalances in mice and in a hamster model of hypercholesterolemia (
15,
16). For
Coriobacteriaceae, strong positive links have been determined with plasma non-high-density lipoprotein (non-HDL) in hamsters (
15). Moreover, Claus and colleagues (
2) showed an association between
Coriobacteriaceae, in particular the genus
Eggerthella, with host metabolism and especially hepatic triglyceride levels in mice. The recurrent identification of associations between
Coriobacteriaceae and
Erysipelotrichaceae, and specific taxa within these families, with host lipid and cholesterol phenotypes in different host species (humans, mice, and hamsters) suggests a genuine link between these bacterial groups and the host lipid metabolism (
2,
14,
15).
The important similarities between hamsters and humans in terms of lipid profiles, enzymatic pathways in lipoprotein and bile metabolism, and susceptibility to diet-induced atherosclerosis pose advantages in using these animals to investigate functional interactions between cholesterol metabolism and the gut microbiota (
17). In a previous study, we used the hamster model of hypercholesterolemia and investigated the interplay between grain sorghum lipid extract in the diet, gut microbial ecology, and cholesterol metabolism. This study showed that specific bacterial groups in the fecal samples were tightly linked to diet-induced improvements in host cholesterol metabolism (
15). In particular,
Coriobacteriaceae and unclassified members of the
Erysipelotrichaceae were negatively correlated with non-HDL cholesterol and cholesterol absorption, while bifidobacteria showed positive correlations with HDL cholesterol. Some of these correlations were highly significant, but the directionality of these interactions was not established. Unfortunately, hamsters cannot be reared germ free (
18), which precludes the study of causation between specific bacterial taxa and host cholesterol metabolism employing gnotobiotic approaches. However, it is possible to specifically modulate the hamster's cholesterol metabolism and study the effects on the gut microbiota. For example, plant sterols and their esters offer an opportunity to modulate cholesterol metabolism in hamsters (
19). These compounds reduce cholesterol absorption in the intestine by a displacement of cholesterol by the plant sterol in intestinal micelles, by cocrystallization between plant sterols and cholesterol leading to the formation of insoluble crystals, and by impeding cholesterol hydrolysis by lipases and cholesterol esterases (
20–26). The chemical processes by which plant sterols exert their actions have been extensively studied
in vitro and do not require the participation of intestinal bacteria.
In this study, we have characterized the fecal microbiota of hamsters whose cholesterol metabolism was extensively modulated by dietary addition of plant sterol esters (
19). In these hamsters, plant sterol ester (PSE) intake reduced cholesterol absorption and increased cholesterol excretion and, consequently, decreased plasma non-HDL cholesterol and liver esterified cholesterol levels. Pyrosequencing of 16S rRNA tags revealed that PSE also induced dramatic shifts in the fecal microbiota with remarkably high correlations with host cholesterol metabolites. Most importantly, the associations between several bacterial taxa with fecal and biliary cholesterol excretion showed an excellent fit to a nonlinear sigmoidal inhibitory model used to describe dose-response relationships between bacteria and inhibitory compounds (
27,
28), suggesting that host cholesterol excretion can shape microbial community structure through the antimicrobial action of cholesterol excreted in the gut.
DISCUSSION
In this study, we have characterized the interplay between the gut microbiota and cholesterol metabolism in hamsters treated with PSE. The study revealed that PSE-induced alterations of cholesterol metabolism were tightly associated with specific compositional shifts of the gut microbiota. The strongest associations were identified between the families Coriobacteriaceae and Erysipelotrichaceae, and several OTUs within these families, and host cholesterol concentrations in plasma, the liver, and fecal samples. Although it is difficult to determine cause-effect relationships among these associations because of the impossibility of raising hamsters germ free, this study provided several lines of evidence that indicate that the bacterial shifts induced by PSE are a consequence of changes in host cholesterol metabolism.
First, the capability of PSE to decrease cholesterol absorption and ultimately modify the host cholesterol metabolism is based on physicochemical interactions independent of bacterial action. Second, levels of cholesterol derivatives (coprostan-3-one, coprostan-3-ol, and dihydrocholesterol) that are considered to contribute to the cholesterol-lowering activity of the gut microbiota were not affected by PSE and showed no association with host cholesterol phenotypes. Third, PSE have not been described to be antibacterial and therefore are unlikely to directly cause the dramatic shifts in the microbiota when added to the diet. In contrast, cholesterol derivatives, and especially cholesterol-linoleate, have been shown to be antibacterial (
36,
37), and associations between several bacterial taxa affected by dietary PSE with fecal and biliary cholesterol excretion showed an excellent fit to a sigmoidal inhibitory nonlinear model of dose-response relationships between bacteria and inhibitory compounds (
Fig. 3). Fourth, fecal cholesterol excretion was negatively associated with bacterial taxa when only hamsters in the control treatment were considered.
The data obtained in this study therefore suggest that changes in host cholesterol metabolism induced through dietary PSE were the main drivers of the modulation in gut microbiota composition. A schematic summary illustrating the physiological processes that are likely to have caused the PSE-induced associations between host cholesterol metabolism and the gut microbiota is shown in
Fig. 5. Intake of PSE decreased plasma and liver cholesterol levels through an inhibition of both dietary and biliary cholesterol absorption in the small intestine, with a consequent increase in fecal cholesterol excretion (
Fig. 5A). In order to maintain cholesterol homeostasis, the host compensated for the decrease in the total cholesterol pool by increasing cholesterol synthesis (
Fig. 5B), which resulted in a further increase of bile-excreted cholesterol. The combination of higher biliary cholesterol excretion and decreased cholesterol absorption resulted in increased concentrations of free and esterified cholesterol in the gastrointestinal tract. These cholesterol derivatives exert an antibacterial effect on specific members of the gastrointestinal microbiota, causing alterations in the microbial community. Since cholesterol excretion strongly correlated with plasma cholesterol levels, the antimicrobial effect of cholesterol is ultimately causing detectable correlations between specific bacterial taxa and host plasma and liver cholesterol levels (
Fig. 5B).
The findings obtained in this study are relevant to our understanding of the gut microbiota-host lipid metabolism interplay. The linkages between the gut microbiota and cholesterol metabolism found in PSE-treated hamsters recapitulated previous findings for hamsters fed grain sorghum lipid extracts (GSL) (
15). In addition, negative correlations between
Coriobacteriaceae and
Erysipelotrichaceae with fecal cholesterol excretion were also detected by our group in an independent experiment with hamsters that were fed whole sorghum kernels (I. Martínez, T. P. Carr, C. L. Weller, and J. Walter, unpublished observations). Bacterial taxa within the families
Coriobacteriaceae and
Erysipelotrichaceae have been recurrently associated with host dyslipidemic phenotypes in mice and humans in the context of obesity, metabolic syndrome, and hypercholesterolemia (
8,
9,
16). If microbiome alterations contributed to lipidmic aberrancies, they could constitute pharmaceutical targets to improve host metabolic functions. In fact, we have previously suggested
Coriobacteriaceae as therapeutic targets to improve host cholesterol metabolism (
15). However, the data obtained with PSE-treated hamsters suggest that the strong associations between
Coriobacteriaceae and
Erysipelotrichaceae and host cholesterol metabolism are caused by the host phenotype affecting the bacteria. Analogous interactions could exist in mice and humans, especially in relation to metabolic disorders that are associated with an altered cholesterol metabolism, such as obesity and the metabolic syndrome. The findings also indicate that diet can modulate gut microbiota composition through an effect on host metabolism, which has also been demonstrated for dietary fat-induced changes in host bile acid composition (
38).
The findings obtained from PSE-treated hamsters provided the first evidence for a role of cholesterol as a relevant host factor that modulates the gut microbiota. The
in vitro assays performed in this study confirmed the antibacterial effect of cholesteryl-linoleate on selected strains of gut bacteria. Although the antibacterial effect detected in the
in vitro experiments was modest, even small levels of inhibition could be relevant under the competitive conditions in the gastrointestinal tract, where even a minor reduction in growth rate could translate into a significant ecological disadvantage. It is important to point out that the approximate concentrations of cholesterol in the
in vitro experiments, due to experimental limitations, were around 20 times lower than those present in the gut of hamsters during PSE treatment. Interestingly, cholesterol and its derivatives have antibacterial activity in the nose and eye epithelial linings (
36,
37). In addition, the findings of Do and coworkers suggest that the antibacterial effect of cholesterol-esters in nasal fluid acts in synergism with that of the α-defensin HNP-2 (
36). Enteric defensins play a significant role in regulating the gut microbiota (
39), and the strong inhibitory effects of cholesterol detected in hamsters therefore might be caused by a synergistic effect of the two compounds. Clearly, the
in vitro experiments on the antibacterial effects of cholesterol included in this study are only preliminary, and further research should be targeted towards elucidating the role of cholesterol as a host factor that modulates the gut microbiota.
Bile acids, which are synthesized from cholesterol, also have antimicrobial activity (
40,
41). Bile acids have been demonstrated to modulate gut microbiota composition (
38,
42), and since the concentration and composition of excreted bile are influenced by dietary fat, bile acids have been suggested to be one cause for the dysbiosis that is associated with obesity-related pathologies (
14). However, bile acids did not appear to be a contributing factor in the population shifts observed in PSE-treated hamsters, as fecal bile acid excretion was reduced by PSE and showed significant positive correlations with the bacteria of the
Coriobacteriaceae and
Erysipelotrichaceae families that were affected by PSE. Although the reduction of bile excretion in PSE-treated hamsters was likely caused by the smaller cholesterol pool, only fecal cholesterol showed highly significant correlations with both the improvements in host lipid metabolism and the abundance of bacterial taxa.
Although this study revealed an example of how a host metabolic factor influences the gut microbiota composition, research with germ-free animals has clearly shown that gut microbes impact host metabolism (including cholesterol metabolism), and it is likely that some alterations of the gut microbiome associated with host metabolism have functional consequences for the host (
12,
43–45). Specific bacterial taxa have been determined to improve lipid markers in the host. Bifidobacteria, which showed positive associations with plasma HDL cholesterol in our previous study (
15), have been identified to alleviate dyslipidemia and high-fat-induced insulin resistance when administered as probiotics (
46–50). In addition, some changes in gut microbiota composition induced through host factors might still have pathological consequences, as shown recently for a fat-induced pathobiont expansion caused by changes in the bile acid pool (
38). Given that the gut microbiota reduces liver and plasma cholesterol levels (
11,
12), we cannot exclude that the dramatic changes in
Coriobacteriaceae and
Erysipelotrichaceae contribute to the cholesterol-lowering effects of PSEs. However, the findings obtained in this study provide evidence that interactions between the gut microbiota and host metabolism are bidirectional, and some patterns of dysbiosis associated with metabolic dysfunctions might be a consequence rather than a cause of the host phenotype.